You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19-CART

Showing 1 - 25 of 9,139
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Systemic Lupus Erythematosus Trial in Shanghai (Relma-cel)

Recruiting
  • Systemic Lupus Erythematosus
  • Relma-cel
  • Shanghai, China
    Relma-cel Medical
Mar 12, 2023

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022

Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

Not yet recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoma, Non-Hodgkin
  • CART-19
  • Ribeirao Preto, Sao Paulo, Brazil
    Ribeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • +2 more
  • PACE CART19
  • (no location specified)
Mar 9, 2022

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With CNS

Active, not recruiting
  • Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
  • +2 more
  • Murine CART19
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 11, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Acute Leukemia Trial in Shanghai (CD19 CART)

Completed
  • Acute Leukemia
  • CD19 CART
  • Shanghai, Shanghai, China
    Shanghai Bioray Inc.
Sep 20, 2020

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Lymphoblastic Leukemia, Acute, Childhood Trial in Philadelphia (Tocilizumab, CART 19)

Completed
  • Lymphoblastic Leukemia, Acute, Childhood
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jun 30, 2021

Acute Lymphoid Leukemia Trial in Spain (ARI-0001 cells)

Recruiting
  • Acute Lymphoid Leukemia
  • ARI-0001 cells
  • Badalona, Barcelona, Spain
  • +9 more
Feb 3, 2022

Multiple Myeloma Trial in Shanghai (GC012F injection)

Unknown status
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 21, 2021

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

Active, not recruiting
  • Multiple Myeloma
  • BCMA CART + huCART19
  • +2 more
  • Philadelphia, Pennsylvania
    Univ. of Pennsylvania
Jul 11, 2022